Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
08/29/2012
Trade Name:
Afinitor Disperz
Generic Name or Proper Name (*):
everolimus
Indications Studied:
Treatment of subependymal giant cell astrocytoma (SEGA) in patients with tuberous sclerosis complex (TSC)
Label Changes Summary:
Approved for patients 1 year and older with TSC for the treatment of SEGA that requires therapeutic intervention but cannot be curatively resected The safety and effectiveness of Afinitor Tablets and Afinitor Disperz have not been established in pediatric patients with renal angiomyolipoma with TSC in the absence of SEGA The effectiveness in pediatric patients with SEGA was demonstrated in two clinical trial The long term effects of Afinitor on growth and pubertal development are unknown Information on starting dose, therapeutic drug monitoring, clinical trial, and adverse reactions New formulation
Product Labeling:
Labeling
BPCA(B):
B
Sponsor:
Novalar Pharmaceuticals, Inc.
Pediatric Exclusivity Granted Date:
07/10/2012
NNPS:
FALSE'
Therapeutic Category:
Antineoplastic
-
-